Abstract
Structural rearrangements of the genome can drive lung tumorigenesis through the generation of fusion genes with oncogenic properties. Advanced genomic approaches have identified the presence of a genetic fusion between fibroblast growth factor receptor 3 (FGFR3) and transforming acidic coiled-coil 3 (TACC3) in non-small cell lung cancer (NSCLC), providing a novel target for FGFR inhibition. To interrogate the functional consequences of the FGFR3–TACC3 fusion in the transformation of lung epithelial cells, we generated a novel transgenic mouse model that expresses FGFR3–TACC3 concomitant with loss of the p53 tumor suppressor gene. Intranasal delivery of an Ad5-CMV-Cre virus promoted seromucinous glandular transformation of olfactory cells lining the nasal cavities of FGFR3–TACC3 (LSL–F3T3) mice, which was further accelerated upon loss of p53 (LSL–F3T3/p53). Surprisingly, lung tumors failed to develop in intranasally infected LSL–F3T3 and LSL–F3T3/p53 mice. In line with these observations, we demonstrated that intranasal delivery of Ad5-CMV-Cre induces widespread Cre-mediated recombination in the olfactory epithelium. Intra-tracheal delivery of Ad5-CMV-Cre into the lungs of LSL–F3T3 and LSL–F3T3/p53 mice, however, resulted in the development of lung adenocarcinomas. Taken together, these findings provide in vivo evidence for an oncogenic function of FGFR3–TACC3 in respiratory epithelium.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Society AC. Cancer facts & figures 2016. Atlanta: American Cancer Society; 2016.
George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53.
Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.
Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–25.
Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 2018;23:227–38 e3.
Soda M, Young Lim C, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.
Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371:2167–77.
Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol. 2013;230:270–6.
Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.
Yuan L, Liu Z-H, Lin Z-R, Xu L-H, Zhong Q, Zeng M-S. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol Ther. 2014;15:1613.
Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337:1231–5.
Carneiro BA, Elvin JA, Kamath SD, Ali SM, Paintal AS, Restrepo A, et al. gTACC3: a novel gene fusion in cervical cancer. Gynecol Oncol Rep. 2015;13:53–6.
Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Human Mol Genet. 2013;22:795–803.
Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park S-I, Kim J, et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res. 2014;20:6551–8.
Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Investig. 2013;123:855–65.
Kwon MC, Berns A. Mouse models for lung cancer. Mol Oncol. 2013;7:165–77.
Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006;5:741–54.
Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010;70:9827–36.
Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci Usa. 2008;105:19893–7.
Ferone G, Song JY, Sutherland KD, Bhaskaran R, Monkhorst K, Lambooij JP, et al. SOX2 is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell. 2016;30:519–32.
Yin Y, Betsuyaku T, Garbow JR, Miao J, Govindan R, Ornitz DM. Rapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3. Cancer Res. 2013;73:5730–41.
DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009;4:1064–72.
Arimoto Y, Nagata H, Isegawa N, Kumahara K, Isoyama K, Konno A, et al. In vivo expression of adenovirus-mediated lacZ gene in murine nasal mucosa. Acta Otolaryngol. 2002;122:627–33.
Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE. 2011;6:e20351.
Huijbers IJ, Bin Ali R, Pritchard C, Cozijnsen M, Kwon MC, Proost N, et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med. 2014;6:212–25.
Rock JR, Onaitis MW, Rawlins EL, Lu Y, Clark CP, Xue Y, et al. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc Natl Acad Sci USA. 2009;106:12771–5.
Jonkers J,Meuwissen R,Gulden Hvd,Peterse H,Valk Mvd,Berns A, Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breat cancer. Nat Genet. 2001;29:418–25.
Hatch TF, Gross P. Pulmonary deposition and retention of inhaled aerosols. New York: Academic Press; 1964.
Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. PNAS. 2001;98:6074–9.
Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, et al. A Lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997;89:693–702.
Nelson KN, Meyer AN, Siari A, Campos AR, Motamedchaboki K, Donoghue DJ. Oncogenic gene fusion FGFR3-TACC3 is regulated by tyrosine phosphorylation. Mol Cancer Res. 2016;14:458-69.
Daly C, Castanaro C, Zhang W, Zhang Q, Wei Y, Ni M, et al. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Oncogene. 2016;36:471–81.
Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593–605.
Johnson VJ, Yucesoy B, Reynolds JS, Fluharty K, Wang W, Richardson D, et al. Inhalation of toluene diisocyanate vapor induces allergic rhinitis in mice. J Immunol. 2007;179:1864–71.
Sutherland KD, Proost N, Brouns I, Adriaensen D, Song J-Y, Berns A. Cell of Origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell. 2011;19:754–64.
Leung C, Coulombe P, Reed R. Contribution of olfactory neural stem cells to tissue maintenance and regeneration. Nat Neurosci. 2007;10:720–6.
Duggan C, Ngai J. Scent of a stem cell. Nat Neurosci. 2007;10:673–4.
Damjanovic D, Zhang X, Mu J, Fe Medina M, Xing Z. Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector. Genet Vaccines Ther. 2008;6:5.
Doi K, Nibu K, Ishida H, Okado H, Terashima T. Adenovirus-mediated gene transfer in olfactory epithelium and olfactory bulb: a long-term study. Ann Ontol Rhinol Larygol. 2005;114:629–33.
Zhao H, Otaki J, Firestein S. Adenovirus-mediated gene transfer in olfactory neurons in vivo. J Neurobiol. 1996;30:521–30.
Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005;65:10280–8.
Mollaoglu G, Guthrie MR, Bohm S, Bragelmann J, Can I, Ballieu PM, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31:270–85.
Sutherland KD, Song JY, Kwon MC, Proost N, Zevenhoven J, Berns A. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci USA. 2014;111:4952–7.
Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell. 2013;50:185–99.
Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7:596–609.
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
Mukhopadhyay A, Berrett KC, Kc U, Clair PM, Pop SM, Carr SR, et al. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep. 2014;8:40–9.
Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol. 2010;4:397–403.
Weeden CE, Chen Y, Ma SB, Hu Y, Ramm G, Sutherland KD, et al. Lung basal stem cells rapidly repair DNA damage using the error-prone nonhomologous end-joining pathway. PLoS Biol. 2017;15:e2000731.
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48:607–16.
Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell. 2014;25:590–604.
Best SA, Nwaobasi AN, Schmults CD, Ramsey MR. CCAR2 is required for proliferation and tumor maintenance in human squamous cell carcinoma. J Invest Dermatol. 2017;137:506–12.
Beard C, Hochedlinger K, Plath K, Wutz A, Jaenisch R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis. 2006;44:23–8.
Leong HS, Chen K, Hu Y, Lee S, Corbin J, Pakusch M, et al. Epigenetic regulator Smchd1 functions as a tumor suppressor. Cancer Res. 2013;73:1591–9.
Best SA, De Souza DP, Kersbergen A, Policheni AN, Dayalan S, Tull D, et al. Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment. Cell Metab. 2018;27:935–43 e4.
Best SA, Kersbergen A, Asselin-Labat ML, Sutherland KD. Combining cell type-restricted adenoviral targeting with immunostaining and flow cytometry to identify cells-of-origin of lung cancer. Methods Mol Biol. 2018;1725:15–29.
Acknowledgements
We are grateful to C. Alvarado, L. Scott, H. Johnson, K. Birchall, and L. Mackiewicz for animal husbandry, E. Tsui and C. Tsui in the WEHI Histology Facility for expert support and P. Maltezos for preparation of the nasal cavity graphic image. The authors thank T. Wilson, J. Mighall, and J. Pasquet for technical support and W. Alexander for useful discussions and critically reading the manuscript. This work was supported in part by a Worldwide Cancer Research Project Grant [14–0433]. SAB is supported by a Victorian Cancer Agency (VCA) Early Career Seed Grant (ECSG16001); M-LA-L is supported by a Viertel Foundation Senior Medical Research Fellowship; KDS is supported by the Peter and Julie Alston Centenary Fellowship. This work was made possible through Victorian Government Operational Infrastructure Support and Australian Government.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Best, S.A., Harapas, C.R., Kersbergen, A. et al. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene 37, 6096–6104 (2018). https://doi.org/10.1038/s41388-018-0399-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-018-0399-5